Benitec Biopharma Inc.

Benitec Biopharma Inc.

NNASDAQ:BNTC
8.54
USD
-0.50
(-5.53%)
-1.10EPS
348.89MMarket Cap
Feb 15Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
31.75
1.38
0.45
0.28
4.98
229.2
1.61
0.23
0.15
0.05
- -
- -
- -
- -
Basic EPS, GAAP
-373.76
-14.74
-24.22
-4.8
-153.47
51.77
-137.74
-54.94
-37.88
-14.12
-1.18
-1.05
-0.98
-1.1
Free Cash Flow per Basic Share
-548.31
-16.83
-26.79
-9.27
- -
87.03
-127.02
-51.66
-33.1
-13
-1.07
-0.65
-0.36
-0.38
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
81.75
36.53
21.44
18.61
11.9
19.37
157.03
41.63
6
0.12
4.68
3.71
5.14
4.86
Tangible Book Value per Share
81.75
36.53
21.44
18.61
11.9
19.37
157.03
41.63
6
0.12
4.68
3.71
5.14
4.86
Basic Weighted Avg Shares
- -
- -
1
1
- -
- -
- -
- -
- -
1
18
36
47
45
Sales/Revenue/Turnover
1
1
- -
- -
- -
12
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-1,234.45
-965.59
-4,606.25
-1,702.7
-3,143.92
22.36
-8,537.11
-23,044.07
-24,457.53
-25,441.33
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-7
-7
-14
-3
-6
3
-8
-14
-18
-20
-22
-38
-46
-50
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,177.09
-1,064.66
-5,340.09
-1,708.71
-3,079.37
22.59
-8,529.9
-23,528.81
-24,942.47
-26,082.67
- -
- -
- -
- -
Working Capital
32
14
10
12
10
16
10
19
2
- -
47
97
176
169
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
Total Equity
32
14
10
13
10
17
10
20
3
- -
47
97
177
170
Return on Invested Capital (%)
- -
- -
- -
- -
- -
19.28
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
19.48
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-22.24
-29.77
-112.06
-29.03
-55.25
19.48
-61.67
-91.79
-159.08
-1,268.61
-91.68
-52.46
-33.21
-37.61

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'27
ST Debt
- -
- -
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
34
35
Market Capitalization
366
460
349

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'27
Total Current Assets
186
182
178
Cash, Cash Equivalents & STI
185
180
176
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
5
9
Payables & Accruals
2
4
8
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2,342.09%
4,659.87%
81.93%
Free Cash Flow
- -
6.96%
-29.58%
Net Income, GAAP
-33.38%
28.85%
20.12%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.18
-0.26
-0.38
-0.39
-1.05
2026
-0.22
-0.26
-0.24
-0.37
-0.98
2027
-0.26
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
Jerel A. Banks
Full Time Employees
24
Sector
Health technology
Industry
Biotechnology
Address
3940 Trust Way Hayward CA United States 94545
IPO Date
Jul 11, 2012
Business
Benitec Biopharma Inc. is a clinical-stage biotechnology company headquartered in Hayward, California, specializing in the development of novel genetic medicines using its proprietary DNA-directed RNA interference (ddRNAi) platform. This platform combines RNA interference with gene therapy to create treatments that enable sustained silencing of disease-causing genes following a single administration, while simultaneously delivering wildtype replacement genes to restore normal cellular function. Its core products and services focus on the development of silence and replace-based therapeutics for chronic and life-threatening genetically defined diseases, with its lead product candidate BB-301, an AAV-based gene therapy designed to treat oculopharyngeal muscular dystrophy (OPMD) by silencing the mutant gene while replacing it with a functional version. In recent developments, Benitec Biopharma reported positive interim results from its Phase 1b/2a clinical trial of BB-301, achieving a 100% responder rate in the first cohort, and received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for dysphagia associated with OPMD, which is expected to expedite its clinical development and regulatory review. The company also completed a $100 million equity financing in November 2025 to fund ongoing development programs. Additionally, Suvretta Capital Management significantly increased its investment holdings in Benitec during late 2024, reflecting strong investor confidence in the company’s genetic medicine technology and growth prospects. Benitec operates primarily in the biotechnology and pharmaceutical industry segments with a focus on genetic therapies targeting rare and underserved diseases. The company’s technology platform is designed to enable long-term gene silencing combined with gene replacement, with applications potentially extending beyond OPMD to other genetically defined conditions. Founded in 1997, Benitec continues to advance its pipeline and collaborate with strategic partners to accelerate the development and commercialization of its genetic medicine therapies globally.

Company News

  • UPDATED -- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update

  • Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update

  • Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301

  • Benitec Biopharma (NASDAQ:BNTC) Share Price Breaks Below 50-Day Moving Average – Here’s What Happened

  • Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

  • Benitec Biopharma (NASDAQ:BNTC) Stock Crosses Below 50 Day Moving Average – Here’s Why

  • After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)

  • Benitec Biopharma (BNTC) Projected to Release Quarterly Earnings on Monday

  • Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

  • AWM Investment Company Inc. Acquires New Position in Benitec Biopharma Limited $BNTC

  • Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

  • Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

  • Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

  • Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

  • Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade

  • Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

  • Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Buys 16,836 Shares

  • Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Acquires 50,000 Shares

  • Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?

  • Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Purchases 10,215 Shares of Stock